The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with bevacizumab； to a pharmaceutical composition comprising ZD6474 and bevacizumab； to a combination product comprising ZD6474 and bevacizumab for use in a method of treatment of a human or animal body by therapy； to a kit comprising ZD6474 and bevacizumab； to the use of ZD6474 and bevacizumab in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.
